Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Lymphoma Aggressive Lymphomas Aggressive Lymphomas:

Aggressive Lymphomas: Cellular and bispecific antibody therapies

(S240) PHASE 1 ALEXANDER STUDY OF AUTO3 THE FIRST BICISTRONIC CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD19 AND CD22 WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Aravind Ramakrishnan, Maria Marzolini, Wendy Osborne, et al.

The authors of the abstract conclude: 
AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade.
 
————————————————————————————————————————————————————————
 
 
Michael J Dickinson, Franck Morschhauser, Gloria Iacoboni, et al. 
 
The authors of the abstract conclude: 

CD20-TCB shows strong clinical efficacy, including durable CRs, and manageable safety in heavily-pretreated NHL pts. Updated safety, efficacy, PK and biomarker data will be presented.

————————————————————————————————————————————————————————
 
 
Ying Liu, Biping Deng, Bo Hu, et al. 
 
The authors of the abstract conclude: 
Our study demonstrated that sequential administration of CAR T cells targeting CD19, CD22 and CD20 may be safe and effective in inducing durable remission and mitigating relapsein children with r/r Burkitt lymphoma.————————————————————————————————————————————————————————
 
 
Andrea Kuhnl, Claire Roddie, Eleni Tholouli, et al.
 
The authors of the abstract conclude: 
The UK national CAR-T service provides an excellent structure for broad, efficient and fair access to licenced CD19 CAR-T products and can serve as a model for implementing cost-intense complex therapies on a national basis. This prospective, unselected real-world population of CAR-T eligible and –treated patients offers valuable insights into the clinical benefit and health economic implications of CD19 CAR-T in daily practice.
 
————————————————————————————————————————————————————————
 
 
Nilanjan Ghosh, Alison Sehgal, Gerhard Hildebrandt, et al. 
 
The authors of the abstract conclude: 
These interim data suggest that elderly and/or comorbid patients with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso-cel with similar safety and efficacy to that previously reported in third-line patients (Abramson, ASH 2019 #241). Updated data with longer follow-up will be presented.